Table 1 Average phase-by-phase attrition rates and phase-by-phase share: 2000–2009 (00), 2010–2013 (10), for the three institutional types under study (pharmaceutical and biotechnological companies, non-industrial institutions)
From: The endless frontier? The recent increase of R&D productivity in pharmaceuticals
Developer | Attrition rates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Preclinical | Phase I | Phase II | Phase III | Registration | ||||||
00 | 10 | 00 | 10 | 00 | 10 | 00 | 10 | 00 | 10 | |
Pharmaceutical | 86.80 | 85.16 | 62.18 | 58.91 | 77.74 | 78.69 | 64.33 | 66.40 | 46.67 | 32.52 |
Biotech | 90.25 | 82.17 | 59.61 | 54.15 | 82.20 | 77.48 | 78.15 | 64.14 | 35.00 | 22.54 |
Non-industrial | 96.97 | 97.07 | 62.37 | 59.32 | 90.00 | 80.19 | 82.14 | 81.25 | 67.65 | 0 |
Share | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Preclinical | Phase I | Phase II | Phase III | Registration | ||||||
Developer | 00 | 10 | 00 | 10 | 00 | 10 | 00 | 10 | 00 | 10 |
Pharmaceutical | 24.16 | 24.44 | 43.99 | 49.15 | 47.56 | 48.34 | 62.26 | 62.36 | 76.69 | 61.19 |
Biotech | 48.60 | 43.19 | 44.54 | 42.51 | 42.18 | 44.18 | 30.55 | 32.41 | 16.36 | 35.32 |
Non-industrial | 27.24 | 32.37 | 11.47 | 8.33 | 10.26 | 7.48 | 7.19 | 5.24 | 6.95 | 3.48 |